or Try an Advanced Search...

    Technical Analysis for BMND - Biomind Labs Inc

    Grade Last Price % Change Price Change
    D 0.460 2.22% 0.010
    BMND closed down 39.19 percent on Wednesday, September 18, 2024, on 33 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent N/A Down Down
    Historical BMND trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 2.22%
    Fell Below 50 DMA Bearish 2.22%
    Narrow Range Bar Range Contraction 2.22%
    Wide Bands Range Expansion 2.22%
    Gapped Down Weakness 2.22%
    Narrow Range Bar Range Contraction -37.84%
    Stochastic Reached Overbought Strength -37.84%
    Wide Bands Range Expansion -37.84%
    Gapped Up Strength -37.84%
    Overbought Stochastic Strength -37.84%
    Older End-of-Day Signals for BMND ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 2 hours ago
    2x Volume Pace about 2 hours ago
    Up 2% about 2 hours ago
    Up 1% about 2 hours ago
    1.5x Volume Pace about 2 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BMND Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Biomind Labs Inc Description

    Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammatory disorders, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Alzheimer's Disease Chronic Pain Pharmaceutical Drugs Depression Fibromyalgia Major Depressive Disorder

    Is BMND a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.09
    52 Week Low 0.025
    Average Volume 3,087
    200-Day Moving Average 0.000
    50-Day Moving Average 0.473
    20-Day Moving Average 0.531
    10-Day Moving Average 0.552
    Average True Range 0.155
    RSI (14) 39.02
    ADX 22.8
    +DI 42.588
    -DI 38.542
    Chandelier Exit (Long, 3 ATRs) 0.275
    Chandelier Exit (Short, 3 ATRs) 0.765
    Upper Bollinger Bands 0.831
    Lower Bollinger Band 0.230
    Percent B (%b) 0.37
    BandWidth 113.188
    MACD Line 0.029
    MACD Signal Line 0.026
    MACD Histogram 0.0026
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.450
    Resistance 3 (R3) 0.450 0.450 0.450
    Resistance 2 (R2) 0.450 0.450 0.450 0.450
    Resistance 1 (R1) 0.450 0.450 0.450 0.450 0.450
    Pivot Point 0.450 0.450 0.450 0.450 0.450
    Support 1 (S1) 0.450 0.450 0.450 0.450 0.450
    Support 2 (S2) 0.450 0.450 0.450 0.450
    Support 3 (S3) 0.450 0.450 0.450
    Support 4 (S4) 0.450